Insmed Inc (NASDAQ:INSM)

24.23
Delayed Data
As of Feb 16
 -1.14 / -4.49%
Today’s Change
11.49
Today|||52-Week Range
33.94
-22.29%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.9B

Company Description

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.

Contact Information

Insmed, Inc.
Building 10
Bridgewater New Jersey 08807-3365
P:(908) 977-9900
Investor Relations:
(908) 947-4326

Employees

Shareholders

Mutual fund holders62.38%
Individual stakeholders4.42%
Other institutional35.53%

Top Executives

Will LewisPresident, Chief Executive Officer & Director
Paolo TombesiChief Financial Officer
Walter R. PerkinsChief Technology Officer
Paul StreckChief Medical Officer
John GollVice President & Corporate Controller